WO2017045751A1 - Composés utilisés en tant qu'inhibiteurs d'asic et utilisations de ceux-ci - Google Patents

Composés utilisés en tant qu'inhibiteurs d'asic et utilisations de ceux-ci Download PDF

Info

Publication number
WO2017045751A1
WO2017045751A1 PCT/EP2016/001531 EP2016001531W WO2017045751A1 WO 2017045751 A1 WO2017045751 A1 WO 2017045751A1 EP 2016001531 W EP2016001531 W EP 2016001531W WO 2017045751 A1 WO2017045751 A1 WO 2017045751A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
nmr
mhz
amine
retention time
Prior art date
Application number
PCT/EP2016/001531
Other languages
English (en)
Inventor
Amanda Sutton
Heike HERING
Daryl Simon Walter
Steve EAST
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of WO2017045751A1 publication Critical patent/WO2017045751A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to compounds that are useful as inhibitors of acid- sensing ion channels (ASIC).
  • ASIC acid- sensing ion channels
  • the invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
  • ASIC channels are proton-gated, voltage-insensitive cation channels activated by extracellular acidosis.
  • ASICs belong to a superfamily which also contains degenerins (DEG) and epithelial sodium channels (ENaC) All members within the ENaC/DEG/ASIC superfamily share the same topology, with the N- and C-termini located inside the cell and a large cysteine-rich extracellular domain.
  • DEG degenerins
  • ENaC epithelial sodium channels
  • four genes encode at least six different ASIC subunits, ASICla, ASIC2a, ASIC2b, ASIC3 and ASIC4.
  • ASICs function as trimers and conduct mostly Na+.
  • the amino acid sequences of ASIC subunits are well conserved between species. For example, the mouse ASICla and the human ASICla share over 99% of their amino acid sequence identity.
  • ASICs are highly expressed in neurons, but are also present in non-neuronal tissues. ASICla and ASIC2a and b are widely expressed in the central nervous system, while almost all subunits are present in sensory neurons of the peripheral nervous system. In peripheral sensory neurons, ASICs have been found on cell bodies and sensory terminals, where they appear to be important for nociception and mechanosensation. In central neurons, ASICs have been found on cell bodies, dendrites and at dendritic spines and have been suggested to contribute to synaptic plasticity. ASICs are activated by extracellular acidosis and their activation induces neuronal depolarization, sometimes associated with direct and indirect Ca2+ entry through voltage-gated calcium channels.
  • ASIC activation can be subject to modulation by extracellular alkalosis, intracellular H, neuropeptides, polyamines, cations, arachidonic acid, lactate, nitric oxide, ATP, serotonin and exogenous modulators such as toxins from venoms, PcTx, APETx2, MitTx, and Mambalgin-1.
  • ASICs have been involved in several physiological processes such as nociception, mechanosensation, blood pressure regulation, synaptic function and plasticity. Growing evidence suggests an involvement of ASICs in anxiety and depression-related disorders.
  • a common feature in neuropathological conditions is acidosis arising from ischemia, inflammation, metabolism or synaptic transmission. Acidosis kills neurons and ASICs have been involved in mediating acid-induced neurotoxicity in neurological disorders such as ischemic stroke, epilepsy, multiple sclerosis, Huntington's disease, Parkinson's disease and spinal cord injury.
  • many types of brain tumors upregulate ASIC expression, which suggests a possible role of ASICs in tumor pathophysiology.
  • Ring A, Ring B, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R a , m, n, and p, is as defined and described in embodiments herein.
  • Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with ASIC. Such diseases, disorders, or conditions include those described herein.
  • the present invention provides for inhibitors of ASIC. In certain aspects, the present invention provides for inhibitors of ASIC la. In some embodiments, such compounds include those of the formulae described herein, or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
  • aliphatic or "aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle” “cycloaliphatie” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-6 aliphatic carbon atoms.
  • aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
  • cycloaliphatie (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C 3 -C 6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
  • Exemplary aliphatic groups are linear or branched, substituted or unsubstituted Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • the term "lower alkyl” refers to a Ci -4 straight or branched alkyl group.
  • Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
  • lower haloalkyl refers to a C 1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, or phosphorus (including, any oxidized form of nitrogen, sulfur, or phosphorus; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4- dihydro-2H-pyrrolyl), ⁇ (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • Ci -8 (or Ci- 6 ) saturated or unsaturated, straight or branched, hydrocarbon chain
  • bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
  • alkylene refers to a bivalent alkyl group.
  • An "alkylene chain” is a polymethylene group, i.e., -(CH 2 ) n - wherein n is a positive integer, preferably from 1 to 6, from
  • a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • alkenylene refers to a bivalent alkenyl group.
  • a substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • halogen means F, CI, Br, or I.
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic and bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members.
  • aryl is used interchangeably with the term “aryl ring”.
  • aryl refers to an aromatic ring system.
  • Exemplary aryl groups are phenyl, biphenyl, naphthyl, anthracyl and the like, which optionally includes one or more substituents.
  • aryl is a group in which an aromatic ring is fused to one or more non— aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
  • heteroaryl and “heteroar-”, used alone or as part of a larger moiety refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
  • heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
  • Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
  • heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
  • Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin- 3(4H)-one.
  • heteroaryl group is optionally mono- or bicyclic.
  • heteroaryl is used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”, any of which terms include rings that are optionally substituted.
  • heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
  • heterocycle As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
  • nitrogen includes a substituted nitrogen.
  • a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen the nitrogen is N (as in 3,4-dihydro- 2H-pyrrolyl), ⁇ (as in pyrrolidinyl), or + NR (as in N-substituted pyrrolidinyl).
  • N an organic radical
  • ⁇ an organic radical
  • + NR an organic radical
  • a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
  • saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
  • heterocycle refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
  • partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
  • partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
  • an "optionally substituted” group has a suitable substituent at each substitutable position of the group, and when more than one position in any given structure is substituted with more than one substituent selected from a specified group, the substituent is either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • Suitable monovalent substituents on R° are independently deuterium, halogen, -(CH 2 )(v- 2 R E , -(haloR*), -(CH 2 )o- 2 OH, -(CH 2 )o- 2 OR*, -(CH 2 ) 0 - 2 CH(OR*) 2 ; -O(haloR'), -CN, -N 3 , -(CH 2 )o- 2 C(0)R e , -(CH 2 )o- 2 C(0)OH, -CCH 2 )o- 2 C(0)OR*, -(CH 2 )o- 2 SR e , -(CH 2 )o- 2 SH, -(CH 2 )o_ 2 NH 2 , -(CH 2 )o-2 HR*, -(CH 2 )o- 2 NR* 2 ,
  • Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -0(CR * 2 ) 2 - 3 0-, wherein each independent occurrence of R * is selected from hydrogen, Ci- ⁇ aliphatic which is optionally substituted as defined below, or an unsubstituted 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on the aliphatic group of R * include halogen, -R*, -(haloR*), -OH, -OR', -O(haloR'), -CN, -C(0)OH, -C(0)OR e , -NH 2 , -NHR*, -NR* 2 , or -N0 2 , wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci- ⁇ aliphatic, -CH 2 Ph, -0(CH 2 )o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R ⁇ , -NR ⁇ 2 , -C(0)Rt, -C(0)ORt, -C(0)C(0)Rt, -C(0)CH 2 C(0)Rt, -S(0>2R ⁇ , -S(0) 2 NR ⁇ 2 , -C(S)NR ⁇ 2 , -C(NH)NR ⁇ 2 , or -N(R ⁇ )S(0) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, Ci-6 aliphatic which is optionally substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ⁇ , taken together with their intervening atom(s) form an un
  • Suitable substituents on the aliphatic group of R ⁇ are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2 , or -NO2, wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH 2 Ph, -0(CH 2 )o-iPh, or a 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • the terms “optionally substituted”, “optionally substituted alkyl,” “optionally substituted “optionally substituted alkenyl,” “optionally substituted alkynyl”, “optionally substituted carbocyclic,” “optionally substituted aryl”, “ optionally substituted heteroaryl,” “optionally substituted heterocyclic,” and any other optionally substituted group as used herein, refer to groups that are substituted or unsubstituted by independent replacement of one, two, or three or more of the hydrogen atoms thereon with typical substituents including, but not limited to:
  • -NH 2 protected amino, -NH alkyl, -NH alkenyl, -NH alkynyl, -NH cycloalkyl, -NH - aryl, -NH -heteroaryl, -NH -heterocyclic, -dialkylamino, -diarylamino, -diheteroarylamino,
  • -S(O)- alkyl - S(O)- alkenyl, - S(O)- alkynyl, - S(O)- carbocyclyl, - S(0)-aryl, - S(0)- heteroaryl, - S(0)-heterocyclyl -SO2NH2, -SO2NH- alkyl, -SO2NH- alkenyl, -S0 2 NH- alkynyl, - S0 2 NH- carbocyclyl, -SO2NH- aryl, -S0 2 NH- heteroaryl, -S0 2 NH- heterocyclyl,
  • -alkyl -alkenyl, -alkynyl, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, heterocycloalkyl, -cycloalkyl, -carbocyclic, -heterocyclic, polyalkoxyalkyl, polyalkoxy, - methoxymethoxy, -methoxyethoxy, -SH, -S- alkyl, -S- alkenyl, -S- alkynyl, -S- carbocyclyl, -S- aryl, -S-heteroaryl, -S-heterocyclyl, or methylthiomethyl.
  • Divalent groups include each group in either directions.
  • the group "- SO 2 H-" in between group X and group Y includes both X-S0 2 NH-Y and Y-SO2NH-X.
  • the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
  • tautomer means each of two or more isomers of a compound that exist together in equilibrium, and are readily interchanged by migration of an atom or group within the molecule.
  • Tautomers are constitutional isomers of organic compounds that readily interconvert by a chemical reaction called tautomerization. This reaction commonly results in the formal migration of a hydrogen atom or proton, accompanied by a switch of a single bond and adjacent double bond (e.g., and in no way limited to this example, compounds of the following tautomers are contemplated by the invention,
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • the group comprises one or more deuterium atoms.
  • a compound of the formula I includes isotope- labeled forms thereof.
  • An isotope-labeled form of a compound of the formula I is identical to this compound apart from the fact that one or more atoms of the compound have been replaced by an atom or atoms having an atomic mass or mass number which differs from the atomic mass or mass number of the atom which usually occurs naturally.
  • isotopes which are readily commercially available and which can be incorporated into a compound of the formula I by well- known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phos-phorus, fluo-rine and chlorine, for example 2 H, 3 H, ,3 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F and 36 CI, respectively.
  • a compound of the formula I, a prodrug, thereof or a pharmaceutically acceptable salt of either which contains one or more of the above-mentioned isotopes and/or other isotopes of other atoms is intended to be part of the present invention.
  • An isotope-labeled compound of the formula I can be used in a number of beneficial ways.
  • an isotope-labeled compound of the formula I into which, for example, a radioisotope, such as 3 H or 14 C, has been incorporated is suitable for medicament and/or substrate tissue distribution assays.
  • radioisotopes i.e. tritium ( 3 H) and carbon- 14 ( 14 C)
  • 3 H tritium
  • 14 C carbon- 14
  • Incorporation of heavier isotopes, for example deuterium ( 2 H) into a compound of the formula I has therapeutic advantages o wing to the higher metabolic stability of this isotope-labeled compound. Higher metabolic stability translates directly into an increased in vivo half-life or lower dosages, which under most circumstances would represent a preferred embodiment of the present invention.
  • An isotope-labeled compound of the formula I can usually be prepared by carrying out the procedures disclosed in the synthesis schemes and the related description, in the example part and in the preparation part in the present text, replacing a non-isotope-labeled reactant by a readily available isotope-labeled reactant.
  • Deuterium ( 2 H) can also be incorporated into a compound of the formula I for the purpose in order to manipulate the oxidative metabolism of the compound by way of the primary kinetic isotope effect.
  • the primary kinetic isotope effect is a change of the rate for a chemical reaction that results from exchange of isotopic nuclei, which in turn is caused by the change in ground state energies necessary for covalent bond formation after this isotopic exchange.
  • Exchange of a heavier isotope usually results in a lowering of the ground state energy for a chemical bond and thus causes a reduction in the rate in rate-limiting bond breakage.
  • the product distribution ratios can be altered substantially.
  • Half-life determinations enable favorable and accurate determination of the extent of the extent to which the improvement in resistance to oxidative metabolism has improved. In this way, it is determined that the half-life of the parent compound can be extended by up to 100% as the result of deuterium-hydrogen exchange of this type.
  • Deuterium-hydrogen exchange in a compound of the formula I can also be used to achieve a favorable modification of the metabolite spectrum of the starting compound in order to diminish or eliminate undesired toxic metabolites. For example, if a toxic metabolite arises through oxidative carbon-hydrogen (C-H) bond cleavage, it can reasonably be assumed that the deuterated analogue will greatly diminish or eliminate production of the unwanted metabolite, even if the particular oxidation is not a rate-determining step. Further information on the state of the art with respect to deuterium-hydrogen exchange may be found, for example in Hanzlik et al., J. Org. Chem.
  • a modulator is defined as a compound that binds to and /or inhibits the target with measurable affinity.
  • a modulator has an IC50 and/or binding constant of less about 50 ⁇ , less than about 5 ⁇ , less than about 1 ⁇ , less than about 500 nM, less than about 100 nM, or less than about 10 nM.
  • measurable affinity and “measurably inhibit,” as used herein, means a measurable change in ASIC activity between a sample comprising a compound of the present invention, or composition thereof, and ASIC, and an equivalent sample comprising ASIC, in the absence of said compound, or composition thereof.
  • the present invention provides a compound of formula I,
  • Ring A is C5-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • each R 1 is independently -R, halogen, -OR, -SR, -CN, -N0 2 , -SO2R, -SOR, -C(0)R, -C0 2 R,
  • Ring B is a 3-7 membered heterocylic ring having 1 -4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • each R 2 is independently -R, halogen, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(0)R, -CO2R,
  • Y is C or N, wherein if Y is N then R 3 is absent;
  • R 3 is -R, halogen, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(0)R, -C0 2 R, -C(0)N(R) 2 , -
  • NRC(0)R NRC(0)R, -NRC(0)N(R) 2 , -NRSChR, or -N(R) 2 ;
  • R 4 is -R, or halogen
  • R s is -R or halogen; each R a is independently hydrogen, or Ci-6 aliphatic, each of which is optionally substituted; each R is independently hydrogen, d-6 aliphatic, C5-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or
  • n 0, 1, or 2;
  • n 0, 1 , or 2;
  • p 0, 1, or 2.
  • Ring A is Ring A is C5-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Ring A is phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctanyl, [4.3.0]bicyclononanyl, [4.4.0]bicyclodecanyl, [2.2.2]bicyclooctanyl, fluorenyl, indanyl, tetrahydronaphthyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carb
  • Ring A is phenyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isoindolinyl, isoindolenyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxadiazolyl, 1 ,2,3-oxadiazolyl, 1,2,4-oxadiazolyl;- l,2,5oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, purinyl, pyranyl, furazanyl,
  • Ring A is phenyl, cyclopropyl, cycopentyl, cyclohexyl, pyrazolyl, pyridinyl, pyrazinyl, oxytanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydronaphthalenyl, or tetrahydroisoquinolinyl.
  • Ring A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ring B is 5 membered heterocylic ring having 1 -4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted.
  • Ring B is dihydrofuro [2,3-6] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, isothiazolyl, isoxazolyl, morpholinyl, oxadiazolyl, 1 ,2,3-oxadiazolyl, 1,2,4-oxadiazolyl;- l ,2,5oxadiazolyl, 1 ,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidiny
  • Ring B is
  • Ring B is
  • Y is C.
  • Y is N.
  • R 3 is H.
  • R 3 is Ci-s aliphatic, C5-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1 -4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or R 3 is halogen, -OR, -SR, -CN, -NO2, -S0 2 R, -SOR, -C(0)R, -CO2R, -C(0)N(R) 2 , -NRC(0)R, -NRC(0)N(R) 2 , -NRS0 2 R, or -N(R) 2 .
  • R 3 is methyl, ethyl, propyl, i-propyl, n-butyl, s-butyl, t-butyl, straight chain or branched pentyl, or straight chain or branched hexyl, each of which is optionally substituted.
  • R 3 is phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctanyl, [4.3.0]bicyclononanyl, [4.4.0]bicyclodecanyl, [2.2.2]bicyclooctanyl, fluorenyl, indanyl, tetrahydronaphthyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carb
  • R 3 is halogen, -OR, -SR, -CN, -N0 2 , -S0 2 R, -SOR,
  • R 3 is ⁇ ; optionally substituted Cs-io aryl an optionally substituted 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; halogen; -CN; -OR; or -N(R) 2 .
  • R 3 is - ⁇ , -F, -CI, -Br, -CN, -N(Me) 2 , -OMe,
  • R 4 is H.
  • R 4 is Ci_6 aliphatic, C5-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted, or halogen.
  • R 4 is H or F.
  • R 5 is H.
  • R 5 is Ci-6 aliphatic, C5-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted, or halogen.
  • R 5 is H or F.
  • each R a is H.
  • each R a is Ci-6 aliphatic, which is optionally substituted.
  • each R a is H or Me.
  • each of Ring A, Ring B, R, R 1 , R 2 , R 3 , R 4 , R 5 , R a , m, n, and p is as defined above and described in embodiments, classes and subclasses above and herein, singly or in combination.
  • the present invention provides a compound of formula I-a,
  • the present invention provides a compound of formula I-b,
  • Ring A, R, R 1 , R 2 , R 4 , R a , m, n, and p is as defined above and described in embodiments, classes and subclasses above and herein, singly or in combination.
  • the present invention provides a compound of formula I-c,
  • Ring A, R, R 1 , R 2 , R 4 , R a , m, n, and p is as defined above and described in embodiments, classes and subclasses above and herein, singly or in combination.
  • the present invention provides a compound of formula I-d,
  • Ring A, R, R 1 , R 4 , R a , m, and n is as defined above and described in embodiments, classes and subclasses above and herein, singly or in combination.
  • the present invention provides a compound of formula I-e,
  • Ring A, Ring B, R, R 1 , R 2 , R 3 , R 4 , R 5 , n, and p is as defined above and described in embodiments, classes and subclasses above and herein, singly or in combination.
  • the present invention provides a compound of formula I-f,
  • Ring B, R, R 1 , R 2 , R 3 , R 4 , R 5 , n, and p is as defined above and described in embodiments, classes and subclasses above and herein, singly or in combination.
  • the present invention provides a compound of formula I-g,
  • Ring A, R, R 1 , R 2 , R 4 , R ⁇ m, n, and p is as defined above and described in embodiments, classes and subclasses above and herein, singly or in combination.
  • the invention provides a compound selected from Table 1 :
  • the present invention provides a compound selected from those depicted above, or a pharmaceutically acceptable salt thereof.
  • the compounds of the invention were synthesized in accordance with the schemes provided in the Examples below.
  • the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • the amount of compound in compositions of this invention is such that is effective to measurably inhibit ASIC, or a mutant thereof, in a biological sample or in a patient.
  • the amount of compound in compositions of this invention is such that is effective to measurably inhibit ASIC, or a mutant thereof, in a biological sample or in a patient.
  • a composition of this invention is formulated for administration to a patient in need of such composition.
  • patient or "subject”, as used herein, means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention refers to a nontoxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that are used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-
  • a "pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • compositions of the present invention are administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention include aqueous or oleaginous suspension. These suspensions are formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • a nontoxic parenterally acceptable diluent or solvent for example as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that are employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil employed includes synthetic mono- or di- glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms are also be used for the purposes of formulation.
  • compositions of this invention are orally administered in any orally acceptable dosage form.
  • exemplary oral dosage forms are capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents are optionally also added.
  • compositions of this invention are administered in the form of suppositories for rectal administration.
  • suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention are also administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches are also used.
  • compositions are formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • exemplary carriers for topical administration of compounds of this aremineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • compositions of this invention are optionally administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and are prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.
  • compositions of the present invention that are optionally combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration.
  • provided compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the compound can be administered to a patient receiving these compositions.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
  • the invention provides a method for inhibiting or antagonizing ASIC in a patient or in a biological sample comprising the step of administering to said patient or contacting said biological sample with a compound according to the invention.
  • the invention is directed to the use of compounds of the invention and/or physiologically acceptable salts thereof, for modulating or inhibiting/antagonizing ASIC.
  • modulation denotes any change in ASIC-mediated signal transduction, which is based on the action of the specific inventive compounds capable to interact with the ASIC target in such a manner that makes recognition, binding and activating possible.
  • the compounds are characterized by such a high affinity to ASIC.
  • the substances are highly selective for ASIC over most other channels in order to guarantee an exclusive and directed recognition with the single ASIC target.
  • the term "recognition" - without being limited thereto - relates to any type of interaction between the specific compounds and the target, particularly covalent or non- covalent binding or association, such as a covalent bond, hydrophobic/ hydrophilic interactions, van der Waals forces, ion pairs, hydrogen bonds, ligand-receptor (enzyme-inhibitor) interactions, and the like.
  • Such association may also encompass the presence of other molecules such as peptides, proteins or nucleotide sequences.
  • the present ion channel interaction is characterized by high affinity, high selectivity and minimal or even lacking cross-reactivity to other target molecules to exclude unhealthy and harmful impacts to the treated subject.
  • the present invention relates to a method for inhibiting or antagonizing ASIC, with at least one compound of formula (I) according to the invention and/or physiologically acceptable salts thereof, under conditions such that said ASIC is inhibited/antagonozied.
  • the system is a cellular system.
  • the cellular system is defined to be any subject provided that the subject comprises cells.
  • the cellular system can be selected from the group of single cells, cell cultures, tissues, organs and animals.
  • the method for modulating ASIC is performed in-vitro.
  • the prior teaching of the present specification concerning the compounds of formula (I), including any embodiments thereof, is valid and applicable without restrictions to the compounds according to formula (I) and their salts when used in the method for inhibiting/antagonizing ASIC.
  • the prior teaching of the present specification concerning the compounds of formula (I), including any embodiments thereof, is valid and applicable without restrictions to the compounds according to formula (I) and their salts when used in the method for inhibiting/antagonizing ASIC.
  • the present invention provides a method for treating an ASIC-mediated disorder comprising the step of administering to a patient in need thereof a compound of the present invention, or pharmaceutically acceptable composition thereof.
  • a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain, arthritis, migrane, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof.
  • a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • a method for the treatment or lessening the severity of radicular pain, sciatica, back pain, head pain, or neck pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • a method for the treatment or lessening the severity of severe or intractable pain, acute pain, postsurgical pain, back pain, tinnitis or cancer pain comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • the compounds of the present invention are useful in the prophylaxis and treatment of autoimmune and/or inflammatory disorders, including neurodegenerative diseases, such as multiple sclerosis (MS), polyneuritis, multiple neuritis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, optic neuritis, or Parkinson's disease.
  • neurodegenerative diseases such as multiple sclerosis (MS), polyneuritis, multiple neuritis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, optic neuritis, or Parkinson's disease.
  • the present invention furthermore relates to a method of treating a subject suffering from an immunerogulatory abnomality, comprising administering to said subject a compound of formula I in an amount that is effective for treating said immunoregulatory abnormality.
  • the present invention preferably relates to a method wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves' ophthalmopathy and asthma.
  • the present invention furthermore relates to a method wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft-versus-host disease.
  • the present invention furthermore relates to a method wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft- versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and postinfectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, sebor
  • the disorder or disease is anxiety.
  • the disorder or disease is optic neuritis.
  • the disorder or disease is MS.
  • the disorder or disease is depression-related disorders
  • the disorder or disease is acidosis. In certain embodiments, the disorder or disease is acidosis arising from ischemia, inflammation, metabolism or synaptic transmission.
  • the disorder or disease is ischemic stroke, epilepsy, multiple sclerosis, Huntington's disease, Parkinson's disease or spinal cord injury.
  • the disorder or disease is cancer.
  • the disorder or disease is brain cancer or brain tumor.
  • an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of a disease or disorder provide supra.
  • the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of a disease or disorder provide supra.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • the compounds of the invention are useful as inhibitors of voltage-gated ion channels.
  • the compounds and compositions of the invention are inhibitors of one or more of ASIC la, ASIC2a, ASIC2b, ASIC3 or ASIC4, and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of ASIC la, ASIC2a, ASIC2b, ASIC3 and ASIC4 is implicated in the disease, condition, or disorder.
  • the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of ASIC la, ASIC2a, ASIC2b, ASIC3 and ASIC4 is implicated in the disease state.
  • the compounds and compositions of the invention are inhibitors of ASIC.
  • the activity of a compound utilized in this invention as an inhibitor of ASIC la, ASIC2a, ASIC2b, ASIC3 or ASIC4 may be assayed according to methods described generally in the examples herein, or according to methods available to one of ordinary skill in the art.
  • the compound is administered in an effective amount as defined above.
  • the treatment is an oral administration.
  • the method of the invention can be performed either in-vitro or in-vivo.
  • the susceptibility of a particular cell to treatment with the compounds according to the invention can be particularly determined by in-vitro tests, whether in the course of research or clinical application.
  • a culture of the cell is combined with a compound according to the invention at various concentrations for a period of time which is sufficient to allow the active agents to inhibit ASIC activity, usually between about one hour and one week.
  • In-vitro treatment can be carried out using cultivated cells from a biopsy sample or cell line.
  • the host or patient can belong to any mammalian species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for treatment of human disease.
  • the compounds according to the invention can also be used as reagents for testing ASIC-dependent signal transduction pathways in animals and/or cell culture models or in the clinical diseases mentioned in this application.
  • the invention also relates to the use of compounds according to formula (I) and/or physiologically acceptable salts thereof for the prophylactic or therapeutic treatment and/or monitoring of diseases that are caused, mediated and/or propagated by ASIC activity. Furthermore, the invention relates to the use of compounds according to formula (I) and/or physiologically acceptable salts thereof for the production of a medicament for the prophylactic or therapeutic treatment and/or monitoring of diseases that are caused, mediated and/or propagated by ASIC activity. In certain embodiments, the invention provides the use of a compound according to formula I or physiologically acceptable salts thereof, for the production of a medicament for the prophylactic or therapeutic treatment of an ASIC-mediated disorder.
  • Compounds of formula (I) and/or a physiologically acceptable salt thereof can furthermore be employed as intermediate for the preparation of further medicament active ingredients.
  • the medicament is preferably prepared in a non-chemical manner, e.g. by combining the active ingredient with at least one solid, fluid and/or semi-fluid carrier or excipient, and optionally in conjunction with a single or more other active substances in an appropriate dosage form.
  • the compounds of formula (I) according to the invention can be administered before or following an onset of disease once or several times acting as therapy.
  • the aforementioned compounds and medical products of the inventive use are particularly used for the therapeutic treatment.
  • a therapeutically relevant effect relieves to some extent one or more symptoms of a disorder, or returns to normality, either partially or completely, one or more physiological or biochemical parameters associated with or causative of a disease or pathological condition.
  • Monitoring is considered as a kind of treatment provided that the compounds are administered in distinct intervals, e.g. in order to boost the response and eradicate the pathogens and/or symptoms of the disease completely. Either the identical compound or different compounds can be applied.
  • the methods of the invention can also be used to reduce the likelihood of developing a disorder or even prevent the initiation of disorders associated with ASIC activity in advance or to treat the arising and continuing symptoms.
  • prophylactic treatment is advisable if the subject possesses any preconditions for the aforementioned physiological or pathological conditions, such as a familial disposition, a genetic defect, or a previously incurred disease.
  • the invention furthermore relates to a medicament comprising at least one compound according to the invention and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  • the invention relates to a medicament comprising at least one compound according to the invention and/or physiologically acceptable salts thereof.
  • a "medicament” in the meaning of the invention is any agent in the field of medicine, which comprises one or more compounds of formula (I) or preparations thereof (e.g. a pharmaceutical composition or pharmaceutical formulation) and can be used in prophylaxis, therapy, follow-up or aftercare of patients who suffer from diseases, which are associated with ASIC activity, in such a way that a pathogenic modification of their overall condition or of the condition of particular regions of the organism could establish at least temporarily.
  • the active ingredient may be administered alone or in combination with other treatments.
  • a synergistic effect may be achieved by using more than one compound in the pharmaceutical composition, i.e. the compound of formula (I) is combined with at least another agent as active ingredient, which is either another compound of formula (I) or a compound of different structural scaffold.
  • the active ingredients can be used either simultaneously or sequentially.
  • Antiinflammatory agents include but are not limited to NSAIDs, non-specific and COX-2 specific cyclooxygenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor (TNF) antagonists, immunosuppressants and methotrexate.
  • NSAIDs include, but are not limited to, ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmetin sodium, and hydroxychloroquine.
  • NSAIDs also include COX-2 specific inhibitors such as celecoxib, valdecoxib, lumiracoxib dnd/or etoricoxib.
  • the anti-inflammatory agent is a salicylate.
  • Salicylates include by are not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.
  • the anti-inflammatory agent may also be a corticosteroid.
  • the corticosteroid may be cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, or prednisone.
  • the anti-inflammatory agent is a gold compound such as gold sodium thiomalate or auranofin.
  • the invention also includes embodiments in which the anti-inflammatory agent is a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
  • a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
  • At least one anti-inflammatory compound is an anti-monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist, such as entanercept, or infliximab, which is an anti-TNF alpha monoclonal antibody.
  • an anti-monoclonal antibody such as eculizumab or pexelizumab
  • TNF antagonist such as entanercept, or infliximab
  • Still other embodiments of the invention pertain to combinations in which at least one active agent is an immunosuppressant compound such as an immunosuppressant compound chosen from methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, and mycophenolate mofetil.
  • an immunosuppressant compound such as an immunosuppressant compound chosen from methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, and mycophenolate mofetil.
  • the compounds of the invention are also used in combination with chemotherapeutic drugs, in particular, drugs that induce apoptosis.
  • chemotherapeutic drugs that can be used in combination with chemosensitizing ASIC inhibitors include topoisomerase I inhibitors (camptothecin or topotecan), topoisomerase II inhibitors (e.g. daunomycin and etoposide), alkylating agents (e.g. cyclophosphamide, melphalan and BCNU), tubulin directed agents (e.g. taxol and vinblastine), and biological agents (e.g. antibodies such as anti CD20 antibody, IDEC 8, immunotoxins, and cytokines).
  • topoisomerase I inhibitors camptothecin or topotecan
  • topoisomerase II inhibitors e.g. daunomycin and etoposide
  • alkylating agents e.g. cyclophosphamide, melphalan and BCNU
  • the disclosed compounds of the formula I can be administered in combination with other known therapeutic agents, including anticancer agents.
  • anticancer agent relates to any agent which is administered to a patient with cancer for the purposes of treating the cancer.
  • the anti-cancer treatment defined above may be applied as a monotherapy or may involve, in addition to the herein disclosed compounds of formula I, conventional surgery or radiotherapy or medicinal therapy.
  • Such medicinal therapy e.g. a chemotherapy or a targeted therapy, may include one or more, but preferably one, of the following anti-tumor agents:
  • Alkylating agents such as altretamine, bendamustine, busulfan, carmustine, chlorambucil, chlormethine, cyclophosphamide, dacarbazine, ifosfamide, improsulfan, tosilate, lomustine, melphalan, mitobronitol, mitolactol, nimustine, ranimustine, temozolomide, thiotepa, treosulfan, mechloretamine, carboquone; apaziquone, fotemustine, glufosfamide, palifosfamide, pipobroman, trofosfamide, uramustine, TH-302 4 , VAL-083 4 ;
  • Platinum Compounds such as carboplatin, cisplatin, eptaplatin, miriplatine hydrate, oxaliplatin, lobaplatin, nedaplatin, picoplatin, satraplatin; lobaplatin, nedaplatin, picoplatin, satraplatin;
  • DNA altering agents such as amrubicin, bisantrene, decitabine, mitoxantrone, procarbazine, trabectedin, clofarabine; amsacrine, brostallicin, pixantrone, laromustine 1 ' 3 ;
  • Topoisomerase Inhibitors such as etoposide, irinotecan, razoxane, sobuzoxane, teniposide, topotecan; amonafide, belotecan, elliptinium acetate, voreloxin;
  • Microtubule modifiers such as cabazitaxel, docetaxel, eribulin, ixabepilone, paclitaxel, vinblastine, vincristine, vinorelbine, vindesine, vinflunine; fosbretabulin, tesetaxel;
  • Antimetabolites such as asparaginase 3 , azacitidine, calcium levofolinate, capecitabine,
  • cladribine cytarabine
  • enocitabine floxuridine
  • fludarabine fluorouracil
  • gemcitabine
  • mercaptopurine methotrexate, nelarabine, pemetrexed, pralatrexate, azathioprine, thioguanine, carmofur; doxifluridine, elacytarabine, raltitrexed, sapacitabine, tegafur 2,3 , trimetrexate;
  • Anticancer antibiotics such as bleomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, levamisole, miltefosine, mitomycin C, romidepsin, streptozocin, valrubicin, zinostatin, zorubicin, daunurobicin, plicamycin; aclarubicin, peplomycin, pirarubicin;
  • Hormones/ Antagonists such as abarelix, abiraterone, bicalutamide, buserelin, calusterone, chlorotrianisene, degarelix, dexamethasone, estradiol, fluocortolone
  • Aromatase inhibitors such as aminoglutethimide, anastrozole, exemestane, fadrozole, letrozole, testolactone; formestane;
  • Small molecule kinase inhibitors such as crizotinib, dasatinib, erlotinib, imatinib, lapatinib, nilotinib, pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, vandetanib, vemurafenib, bosutinib, gefitinib, axitinib; afatinib, alisertib, dabrafenib, dacomitinib, dinaciclib, dovitinib, enzastaurin, nintedanib, lenvatinib, linifanib, linsitinib, masitinib, midostaurin, motesanib, neratinib, orantinib, perifosine, ponatinib, radotinib, rigo
  • Photosensitizers such as methoxsalen 3 ; porfimer sodium, talaporfin, temoporfin;
  • Antibodies such as alemtuzumab, besilesomab, brentuximab vedotin, cetuximab, denosumab, ipilimumab, ofatumumab, panitumumab, rituximab, tositumomab,
  • trastuzumab bevacizumab, pertuzumab 2 ' 3 ; catumaxomab, elotuzumab, epratuzumab, farletuzumab, mogamulizumab, necitumumab, nimotuzumab, obinutuzumab, ocaratuzumab, oregovomab, ramucirumab, rilotumumab, siltuximab, tocilizumab, zalutumumab, zanolimumab, matuzumab > dalotuzumab 1 ' 2 ' 3 , onartuzumab 1 3 , racotumomab 1 , tabalumab 1 ' 3 , EMD-525797 4 , nivolumab 1 ' 3 ;
  • Cytokines such as aldesleukin, interferon alfa 2 , interferon alfa2a 3 , interferon alfa2b 2 > 3 ;
  • Drug Conjugates such as denileukin diftitox, ibritumomab tiuxetan, iobenguane 1123,
  • trastuzumab emtansine prednimustine, trastuzumab emtansine, estramustine, gemtuzumab, ozogamicin, aflibercept;
  • cintredekin besudotox edotreotide, inotuzumab ozogamicin, naptumomab estafenatox, oportuzumab monatox, technetium (99mTc) arcitumomab 1 ' 3 , vintafolide 1 - 3 ;
  • Vaccines such as sipuleucel 3 ; vitespen 3 , emepepimut-S 3 , oncoVAX 4 , rindopepimut 3 , troVax 4 , MGN-1601 4 , MGN-1703 4 ; and
  • the invention provides for a kit consisting of separate packs of an effective amount of a compound according to the invention and/or pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally, an effective amount of a further active ingredient.
  • the kit comprises suitable containers, such as boxes, individual bottles, bags or ampoules.
  • the kit may, for example, comprise separate ampoules, each containing an effective amount of a compound according to the invention and/or pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further active ingredient in dissolved or lyophilized form.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment is administered after one or more symptoms have developed.
  • treatment is administered in the absence of symptoms.
  • treatment is administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment is also continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • the compounds and compositions, according to the method of the present invention are administered using any amount and any route of administration effective for treating or lessening the severity of a disorder provided above.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • Compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention are administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 100 mg/kg and preferably from about 1 mg/kg to about 50 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms optionally contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions are formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation are also a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar— agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl
  • Solid compositions of a similar type are also employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms optionally also comprise buffering agents. They optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as required.
  • Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the invention relates to a method of inhibiting ASIC activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
  • the invention relates to a method of inhibiting ASIC, or a mutant thereof, activity in a biological sample in a positive manner, comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
  • the compounds of the invention can be applied either themselves and/or in combination with physical measurements for diagnostics of treatment effectiveness.
  • Pharmaceutical compositions containing said compounds and the use of said compounds to treat ASIC-mediated conditions is a promising, novel approach for a broad spectrum of therapies causing a direct and immediate improvement in the state of health, whether in human or animal.
  • the orally bioavailable and active new chemical entities of the invention improve convenience for patients and compliance for physicians.
  • the compounds of formula (I), their salts, isomers, tautomers, enantiomeric forms, diastereomers, racemates, derivatives, prodrugs and/or metabolites are characterized by a high specificity and stability, low manufacturing costs and convenient handling. These features form the basis for a reproducible action, wherein the lack of cross-reactivity is included, and for a reliable and safe interaction with the target structure.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Modulation of ASIC, or a mutant thereof, activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, biological specimen storage, and biological assays.
  • Example compounds and their intermediates were analysed by HPLC-MS using a combination of the following instrumentation: Shimadzu, Waters or Micromass ZMD, ZQ or LCT mass spectrometers with an Agilent, Waters or Polymer Labs UV and ELS detector.
  • the HPLC conditions are tabulated below.
  • Micromass MassLynx Operating Software with OpenLynx Browser were used for data acquisition, processing and reporting.
  • Example 49 6-[(l-methyIpiperidin-4-yl)oxy]-lH-indazol-3-amine (46) [00245]
  • the title compound was prepared in a manner analagous to that described for example 34: 0.08 g (66.8%) as a white powder.
  • METCR1416 Hi res (7min) M/Z (ES+) 247, Retention time 0.66 min.
  • Racemic 4-fluoro-6-( ⁇ l-[(oxolan-3-yl]piperidin-4-yl ⁇ methoxy)-lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 33.1 mg (37.8%) as a yellow powder.
  • Racemic 4-fluoro-6-( ⁇ l-[(oxolan-3-yl]piperidin-4-yl ⁇ methoxy)-lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 33.1 mg (37.8%) as a yellow powder.
  • Racemic 6-[l-(l-cyclobutylpiperidin-4-yl)ethoxy]-4-fluoro-lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 0.12 g (26%) as an off white foam.
  • Racemic 6-[l-(l-cyclobutylpiperidin-4-yl)ethoxy]-4-fluoro-lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 0.08 g (18%) as an off white foam.
  • Racemic 4-fluoro-6- ⁇ l-[l-(propan-2-yl)piperidin-4-yl]ethoxy ⁇ -lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 0.01 g (19.5%) as a light pink foam.
  • Racemic 4-fluoro-6- ⁇ 1 -[l-(propan-2-yl)piperidin-4-yl]ethoxy ⁇ -lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 60.6 mg (20%) as a light pink foam.
  • Example 84 Enantiomer 1: 4-fluoro-6-( ⁇ l-[(-)-oxan-3-yl]piperidin-4-yl ⁇ methoxy)-lH- indazol-3-amine (115)
  • Racemic 4-fluoro-6- ⁇ [ 1 -(oxan-3-yl)piperidin-4-yl]methoxy ⁇ - 1 H-indazol-3 -amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 11.9 mg (8.4%) as a tan color powder.
  • Racemic 4-fluoro-6- ⁇ [ 1 -(oxan-3-yl)piperidin-4-yl]methoxy ⁇ - 1 H-indazol-3 -amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 7.2 mg (5.1%) as a beige powder.
  • Racemic 4-fluoro-6- ⁇ [l-(propan-2-yl)pyrrolidin-3-yl]methoxy ⁇ -lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 65 mg (9%) as a brown viscous oil.
  • Racemic 4-fluoro-6- ⁇ [l-(propan-2-yl)pyrrolidin-3-yl]methoxy ⁇ -lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 52 mg (7.2%) as a brown viscous oil.
  • Racemic 6-[( 1 -cyclobutylpyrrolidin-3-yl)methoxy]-4-fluoro-l H-indazol-3 -amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 160 mg (20.2%) as a brown viscous oil.
  • Racemic 6-[(l-cyclobutylpyrrolidin-3-yl)methoxy]-4-fluoro-lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 156 mg (19.5%) as a brown viscous oil.
  • Racemic 6-[(l-ethylpyrrolidin-3-yl)methoxy]-4-fluoro-lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 8 mg (1.4%) as a brown solid.
  • Racemic 6-[(l-ethylpyrrolidin-3-yl)methoxy]-4-fluoro-lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 6 mg (1%) as a brown solid.
  • Racemic 4-fluoro-6-( ⁇ 1 -[4,4,4-trifluorobutan-2-yl]piperidin-4-yl ⁇ methoxy)- 1 H- indazol-3-amineamine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 9.1 mg as a brown solid.
  • Achiral LCMS data MET-uHPLC-AB-101 (7min) M Z (ES+) 208.6, Retention time 1.37 min.
  • Racemic 4-fluoro-6-( ⁇ l-[4,4,4-trifluorobutan-2-yl]piperidin-4-yl ⁇ methoxy>lH- indazol-3-amineamine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 6.8 mg as a brown solid.
  • Achiral LCMS data METCR1416 Hi res (7min) M/Z (ES+) 375, Retention time 2.47 min.
  • Racemic 6-( ⁇ 1 - [ 1 , 1 -difluoropropan-2-yl]piperidin-4-yl ⁇ methoxy)-4-fluoro- 1 H- indazol-3 -amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 3 mg as a brown solid.
  • Racemic 6-( ⁇ l-[l,l-difluoropropan-2-yl]piperidin-4-yl ⁇ methoxy)-4-fluoro-lH- indazol-3 -amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 2.8 mg as a brown solid.
  • Example 104 Enantiomer 1 : 4-fluoro-6- ⁇ [l-(3-methylbutyl)pyrrolidin-3-yl]methoxy ⁇ -lH- indazol-3-amine (169)
  • Racemic 4-fluoro-6- ⁇ [ 1 -(3 -methy lbutyl)pyrrolidin-3-yl]methoxy ⁇ - 1 H-indazol-3- amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 62 mg (9.5%) as an off white solid.
  • Example 105 Enantiomer 2: 4-fluoro-6- ⁇ [-l-(3-methylbutyl)pyrroIidin-3-yl]methoxy ⁇ -lH- indazol-3-amine (137)
  • Racemic 4-fluoro-6- ⁇ [ 1 -(3-methylbutyl)pyrrolidin-3-yl]methoxy ⁇ - 1 H-indazol-3- amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 48 mg (7.4%) as an off white solid.
  • Achiral LCMS data METCR1600 High pH (7 min) M/Z (ES+) 321, Retention time 5.00 min.
  • Racemic 4-fluoro-6- ⁇ [l-(2-methylpropyl)pyrrolidin-3-yl]methoxy ⁇ -lH-indazol-3- amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 88 mg (18.9%) as a light brown solid.
  • Achiral LCMS data METCR1600 High pH (7 min) M/Z (ES+) 307, Retention time 4.63 min.
  • Racemic 4-fluoro-6- ⁇ [l-(2-methylpropyl)pyrrolidin-3-yl]methoxy ⁇ -lH-indazol-3- amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 85 mg (18.3%) as a light brown solid.
  • Racemic 4-fluoro-6- ⁇ [l-methylpyrrolidin-3-yl]methoxy ⁇ -lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified) 40 mg (7.6%) as an off white solid.
  • Racemic 4-fluoro-6- ⁇ [l-methylpyrr0lidin-3-yl]methoxy ⁇ -lH-indazol-3-amine was purified by chiral column chromatography to provide the title compound as a single enantiomer (absolute stereochemistry not specified): 42 mg (8%) as an off white solid.
  • tert-butyl 4-(4-cyano-2,5-difluorophenoxymethyl)piperidine-l-carboxylate 250 mg, 0.71 mmol was dissolved in 1-Butanol (3 ml) in a pressure tube and NH2NH2 ⁇ H20 (172.91 ⁇ , 3.55 mmol) was added. Reaction was heated to 120°C overnight. On consumption of starting material the reaction was diluted with 3ml water and extracted 3 x 5ml with EtOAc. The combined organics were dried over Na2S04. The mixture was purified by column chromatography. The NMR showed there to be about 10% regioisomer, so the desired product was recrystalised from EtOAc / Heptane to yield 73 mg (28.2%) as an off white solid.
  • tert-butyl 4-(4-cyano-3,5-difluorophenoxymethyl)piperidine-l-carboxylate 82%, 500 mg, 1.16 mmol
  • methanol 9ml
  • sodium methanolate 125.72 mg, 2.33 mmol
  • 2-amino-6-fluoro-4-hydroxyphenyI 2-azido-6-fluoro-4-methoxybenzonitrile (75%, 507 mg, 1.98 mmol) was dissolved in anhydrous THF (5ml) to give a yellow solution. The reaction was cooled using an ice bath. 1M trimethylphosphane (2.958 ml) was added drop wise and left stirring for 10 minutes at 0°C before being allowed to warm to room temperature. The reaction was stirred at rt for 2h. 3ml water was added to the reaction and was stirred for 15 minutes, before being evaporated to dryness.
  • Example 151 Enantiomer 1: 4-fluoro-6- ⁇ [trans-3-fluoro-l-(propan-2-yl)piperidin-4- yl]methoxy ⁇ -lH-indazol-3-amine (147)
  • Example 152 Enantiomer 2: 4-fluoro-6- ⁇ [(trans)-3-fluoro-l-(propan-2-yl)piperidin-4- yl]methoxy ⁇ -lH-indazol-3-amine (148)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des composés et des compositions pharmaceutiquement acceptables les contenant, utiles en tant qu'inhibiteurs d'ASIC.
PCT/EP2016/001531 2015-09-15 2016-09-12 Composés utilisés en tant qu'inhibiteurs d'asic et utilisations de ceux-ci WO2017045751A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102015012050.6 2015-09-15
DE102015012050.6A DE102015012050A1 (de) 2015-09-15 2015-09-15 Verbindungen als ASIC-Inhibitoren und deren Verwendungen

Publications (1)

Publication Number Publication Date
WO2017045751A1 true WO2017045751A1 (fr) 2017-03-23

Family

ID=56896505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/001531 WO2017045751A1 (fr) 2015-09-15 2016-09-12 Composés utilisés en tant qu'inhibiteurs d'asic et utilisations de ceux-ci

Country Status (2)

Country Link
DE (1) DE102015012050A1 (fr)
WO (1) WO2017045751A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287353B2 (en) 2016-05-11 2019-05-14 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-1 inhibitors
US10385131B2 (en) 2016-05-11 2019-08-20 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-L1 inhibitors
WO2024112831A1 (fr) * 2022-11-22 2024-05-30 Maze Therapeutics, Inc. Inhibiteurs d'élément 19 de la famille 6a des transporteurs de solutés (slc6a19) et leurs procédés d'utilisation

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843975A (en) * 1995-06-02 1998-12-01 Synthelabo Oxazolidinone derivatives, their preparation and therapeutical use
WO2003051847A1 (fr) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Derives de (1-h-indazol-3-yl) -amide comme inhibiteurs de gsk-3
WO2005063767A2 (fr) * 2003-12-22 2005-07-14 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation
WO2005085206A1 (fr) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Derives d'indazole et compositions pharmaceutiques renfermant ceux-ci
EP1647549A1 (fr) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques
US20070054915A1 (en) * 2005-08-25 2007-03-08 Roche Palo Alto Llc p38 MAP kinase inhibitors and methods for using the same
US20070232620A1 (en) * 2004-06-15 2007-10-04 Dieter Dorsch 3-Aminoindazoles
US7511136B2 (en) * 2001-09-26 2009-03-31 Pfizer Italia S.R.L. Aminoindazole derivatives active as kinase inhibitors
WO2010069966A1 (fr) * 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Dérivés d'indazole substitués actifs en tant qu'inhibiteurs de kinases
WO2010098367A1 (fr) * 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Dérivé de pyrimido-pyrimido-indazole
WO2012152763A1 (fr) * 2011-05-12 2012-11-15 Nerviano Medical Sciences S.R.L. Dérivés d'indazole substitués actifs en tant qu'inhibiteurs de kinases
WO2014144545A2 (fr) * 2013-03-15 2014-09-18 Genentech, Inc. Benzoxazoles substitués et leurs procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578729A4 (fr) * 2002-12-23 2007-08-29 Alcon Inc 1-alkyl-3-aminoindazoles
EP2205085A1 (fr) * 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. Dérivés d'indole 2-aryle ou hétéroaryle
EP2489663A1 (fr) * 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843975A (en) * 1995-06-02 1998-12-01 Synthelabo Oxazolidinone derivatives, their preparation and therapeutical use
US7511136B2 (en) * 2001-09-26 2009-03-31 Pfizer Italia S.R.L. Aminoindazole derivatives active as kinase inhibitors
WO2003051847A1 (fr) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Derives de (1-h-indazol-3-yl) -amide comme inhibiteurs de gsk-3
WO2005063767A2 (fr) * 2003-12-22 2005-07-14 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation
WO2005085206A1 (fr) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Derives d'indazole et compositions pharmaceutiques renfermant ceux-ci
US20070232620A1 (en) * 2004-06-15 2007-10-04 Dieter Dorsch 3-Aminoindazoles
EP1647549A1 (fr) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques
US20070054915A1 (en) * 2005-08-25 2007-03-08 Roche Palo Alto Llc p38 MAP kinase inhibitors and methods for using the same
WO2010069966A1 (fr) * 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Dérivés d'indazole substitués actifs en tant qu'inhibiteurs de kinases
WO2010098367A1 (fr) * 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Dérivé de pyrimido-pyrimido-indazole
WO2012152763A1 (fr) * 2011-05-12 2012-11-15 Nerviano Medical Sciences S.R.L. Dérivés d'indazole substitués actifs en tant qu'inhibiteurs de kinases
WO2014144545A2 (fr) * 2013-03-15 2014-09-18 Genentech, Inc. Benzoxazoles substitués et leurs procédés d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARTUNG INGO V ET AL: "Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 23, no. 8, 14 February 2013 (2013-02-14), pages 2384 - 2390, XP028525192, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.02.028 *
JESSE A. MAY ET AL: "1-(( S )-2-Aminopropyl)-1 H -indazol-6-ol: A Potent Peripherally Acting 5-HT 2 Receptor Agonist with Ocular Hypotensive Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 1, 1 January 2006 (2006-01-01), US, pages 318 - 328, XP055307810, ISSN: 0022-2623, DOI: 10.1021/jm050663x *
SARAH C ABBOT ET AL: "Synthesis of Heteroaryl-fused Pyrazoles as P38 Kinase Inhibitors", HETEROCYCLES COMMUNICATION | SPECIAL ISSUE, JAPAN INSTITUTE OF HETEROCYCLIC CHEMISTRY, JP, vol. 78, no. 11, 1 January 2009 (2009-01-01), pages 2811 - 2826, XP008160162, ISSN: 0385-5414, [retrieved on 20090707], DOI: 10.3987/COM-09-11808 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287353B2 (en) 2016-05-11 2019-05-14 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-1 inhibitors
US10385130B2 (en) 2016-05-11 2019-08-20 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-1 inhibitors
US10385131B2 (en) 2016-05-11 2019-08-20 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-L1 inhibitors
US11535670B2 (en) 2016-05-11 2022-12-27 Huyabio International, Llc Combination therapies of HDAC inhibitors and PD-L1 inhibitors
WO2024112831A1 (fr) * 2022-11-22 2024-05-30 Maze Therapeutics, Inc. Inhibiteurs d'élément 19 de la famille 6a des transporteurs de solutés (slc6a19) et leurs procédés d'utilisation

Also Published As

Publication number Publication date
DE102015012050A1 (de) 2017-03-16

Similar Documents

Publication Publication Date Title
EP3497094B1 (fr) Antagonistes de tlr7/8 et leurs utilisations
US10377745B2 (en) Heterocyclic compounds as NaV channel inhibitors and uses thereof
EP3350170B1 (fr) Composés hétéroaryles en tant qu'inhibiteurs d'irak et leurs utilisations
EP3221306B1 (fr) Dérivés hétérocycliques en tant qu'inhibiteurs du recepteur irak et leurs utilisations
AU2016323612B2 (en) Heteroaryl compounds as IRAK inhibitors and uses thereof
EP3253763B1 (fr) Macrocycles pyridazinone servant d'inhibiteurs d'irak et leurs utilisations
EP3253764B1 (fr) Composés macrocycliques comme inhibiteurs d'irak1/4 et leurs utilisations
EP4248968A2 (fr) Antagonistes de tlr7/8 et leurs utilisations
AU2019313441A1 (en) TLR7/8 antagonists and uses thereof
CA3078579A1 (fr) Composes inhibiteurs de pyrimidine tbk/ikk.epsilon. et leurs utilisations
WO2017045751A1 (fr) Composés utilisés en tant qu'inhibiteurs d'asic et utilisations de ceux-ci
WO2017045750A1 (fr) Composés utilisés en tant qu'inhibiteurs d'asic et utilisations de ceux-ci
WO2019079375A1 (fr) Composés inhibiteurs τβκ/ικκε pyrimidine et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16763448

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16763448

Country of ref document: EP

Kind code of ref document: A1